| Filed |
Name |
|
Company |
Pur. £ |
Cur. £ |
P/L % |
MPV* |
|
Jun '22
|
Lord Sugar
|
|
Acl / NMS:ACLX |
£17.47
|
£72.94
|
317.52%
|
£292,261.05
|
|
Mar '24
|
Lord Moynihan of Chelsea
|
|
Candel Therapeutics / NGM:CADL |
£1.40
|
£5.02
|
258.57%
|
£251,000.00
|
|
May '22
|
Lord Reay
|
|
Novo Nordisk As / NYQ:NVO |
£56.40
|
£140.80
|
149.67%
|
£174,767.27**
|
|
Mar '24
|
Lord Moynihan of Chelsea
|
|
Tg Therapeutics / NCM:TGTX |
£15.05
|
£31.61
|
110.03%
|
£147,023.26
|
|
Jul '25
|
Lord Fink
|
|
Avacta Group / LSE:AVCT.L |
£51.50
|
£78.50
|
52.43%
|
£106,699.03
|
|
May '22
|
Lord Triesman
|
|
Blue / NMS:BLUE |
£3.39
|
£4.97
|
46.61%
|
£102,625.36
|
|
Mar '24
|
Lord Moynihan of Chelsea
|
|
Fortress Biotech / NCM:FBIO |
£1.92
|
£2.69
|
40.10%
|
£98,072.92
|
|
Mar '24
|
Lord Petitgas
|
|
Royalty Pharma / NMS:RPRX |
£30.08
|
£39.60
|
31.65%
|
£92,154.25
|
|
Apr '21
|
Baroness Deech
|
|
Novo Nordisk As / NYQ:NVO |
£36.35
|
£47.57
|
30.87%
|
£91,606.61
|
|
Nov '21
|
Lord Sherbourne of Didsbury
|
|
Novo Nordisk As / NYQ:NVO |
£56.71
|
£70.73
|
24.73%
|
£87,313.29**
|
|
Dec '22
|
Lord Hintze
|
|
Atai Life Sciences / NGM:ATAI |
£3.48
|
£4.06
|
16.67%
|
£81,666.67
|
|
Mar '24
|
Lord Moynihan of Chelsea
|
|
Mustang Bio / NCM:MBIO |
£1.04
|
£1.19
|
14.42%
|
£80,096.16
|
|
Apr '22
|
Lord Hylton
|
|
Genus / LSE:GNS.L |
£2,678.00
|
£2,590.00
|
-3.29%
|
£67,699.78
|
|
Jun '16
|
Lord Lloyd-Webber
|
|
Bb Biotech / EBS:BION.SW |
£47.80
|
£45.45
|
-4.92%
|
£66,558.58
|
|
Nov '24
|
Lord Moynihan of Chelsea
|
|
Sab Biotherapeutics / NCM:SABS |
£3.95
|
£3.70
|
-6.33%
|
£65,569.62
|
|
Mar '17
|
Lord Lloyd-Webber
|
|
Bb Biotech / EBS:BION.SW |
£54.95
|
£45.45
|
-17.29%
|
£57,898.09
|
|
Mar '14
|
Lord Glendonbrook
|
|
Bb Biotech / EBS:BION.SW |
£33.36
|
£27.20
|
-18.47%
|
£57,074.34**
|
|
Aug '23
|
Lord Nash
|
|
Relay / NGM:RLAY |
£10.62
|
£7.83
|
-26.27%
|
£51,610.17
|
|
May '23
|
Lord Stevens of Ludgate
|
|
Avacta Group / LSE:AVCT.L |
£112.00
|
£78.50
|
-29.91%
|
£49,062.50
|
|
Apr '24
|
Lord Grabiner
|
|
Novo Nordisk As / NYQ:NVO |
£127.46
|
£64.73
|
-49.22%
|
£35,549.19**
|
|
Jan '21
|
Lord Spencer of Alresford
|
|
Immupharma / LSE:IMM.L |
£12.65
|
£6.14
|
-51.46%
|
£33,976.28
|
|
Nov '23
|
Lord Mance
|
|
Novo Nordisk As / NYQ:NVO |
£101.69
|
£47.57
|
-53.22%
|
£32,745.60
|
|
Apr '22
|
Lord Spencer of Alresford
|
|
Oxford Nanopore / LSE:ONT.L |
£320.00
|
£131.90
|
-58.78%
|
£28,853.12
|
|
Apr '24
|
Lord Willoughby de Broke
|
|
Novo Nordisk As / NYQ:NVO |
£122.75
|
£47.57
|
-61.25%
|
£27,127.49
|
|
May '24
|
Lord Londesborough
|
|
Novo Nordisk As / NYQ:NVO |
£134.66
|
£47.57
|
-64.67%
|
£24,728.20
|
|
Mar '24
|
Lord Petitgas
|
|
Moderna / NMS:MRNA |
£111.98
|
£25.18
|
-77.51%
|
£15,740.31
|
|
Sep '21
|
Lord Darzi of Denham
|
|
Oxford Nanopore / LSE:ONT.L |
£612.60
|
£131.90
|
-78.47%
|
£15,071.82
|
|
Oct '15
|
Lord Hayward
|
|
Sage / NGM:SAGE |
£46.11
|
£8.68
|
-81.18%
|
£13,177.19
|
|
May '11
|
Lord Glendonbrook
|
|
Mesoblast / NMS:MESO |
£101.20
|
£16.93
|
-83.27%
|
£11,710.47
|
|
May '20
|
Lord Wolfson of Aspley Guise
|
|
Adc Therapeutics / NYQ:ADCT |
£30.00
|
£3.95
|
-86.83%
|
£9,216.67
|
|
Apr '19
|
Lord Nash
|
|
Eq / NCM:EQ |
£8.20
|
£0.69
|
-91.59%
|
£5,890.24**
|
|
Mar '24
|
Lord Moynihan of Chelsea
|
|
Avenue Therapeutics / NCM:ATXI |
£12.00
|
£0.76
|
-93.66%
|
£4,436.25
|
|
Mar '23
|
Baroness Shields
|
|
Benevolentai / AMS:BAI.AS |
£2.46
|
£0.09
|
-96.14%
|
£2,703.25**
|
|
Mar '24
|
Lord Moynihan of Chelsea
|
|
Adaptimmune / NMS:ADAP |
£1.47
|
£0.04
|
-97.12%
|
£2,016.19
|
|
Dec '22
|
Lord Hintze
|
|
Affimed / NGM:AFMD |
£21.20
|
£0.18
|
-99.14%
|
£599.29
|
* Minimum Potential Value based on £70,000.00 invested at time of declaration.
** Interest ceased/exited on filed date.